August #104 : The Multidrug-Resistance Challenge - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Don't Mess With These Girls

Boiling Point

You Go, Uganda

Miami Vice

Mighty Avengers

Firing Squad for Docs?

Earthwatch

Risky Business

Pos & Neg

Blog Rollin’

Briefs

Milestones

The Normal Heartache

Film Review: Monkey Business

Carb Your Enthusiasm

Partner Briefs

The Tao of Toe

Read My Lipo

His 'n' Her Hormones

Budding Romance

The Multidrug-Resistance Challenge

Growing Pains

Check, Please

Founder's Letter

Mailbox

With Honors



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

August 2004

The Multidrug-Resistance Challenge

by Tim Murphy

Houston is home to the Astros and Rockets, but in April it hosted nearly 50 high-flying stars in HIV research and activism who gathered to brainstorm how to better serve multidrug-resistant (MDR) HIVers who desperately need new treatment options (see “The Clockwatchers,” POZ, October 2003). The message was familiar: The best hope for MDR HIVers is getting them two or more brand-new drugs at a time (and ASAP!) to try to overpower dense resistance. But drugmakers—each pursuing data to move its own drug toward approval—have done little to synchronize research toward that goal, even though the FDA long ago gave them the green light.

At one point, all eyes were on Eric Lefebvre, MD, from the smallish pharma Tibotec. Tibotec has two new candidates—the protease inhibitor (PI) TMC 114 and the non-nuke TMC 125—in similar development stages (both in Phase IIb, where dosing levels are determined), hence a rare chance to test them together in MDR HIVers. Would they? “The commitment is there,” Lefebvre ventured. POZ followed up in May, when Tibotec VP Karen Manson confirmed that the company was “already planning to study” both drugs together and “will not need to be encouraged…to initiate [a trial] at the earliest practical moment.”

But Rob Camp of the AIDS Treatment Activist Coalition (ATAC), which aims to represent HIVers in the drug-development process, disagrees: “Although they feel they don’t need encouragement, I encourage them to speed up in order to initiate a combo study by September 2004.”

Option-needy HIVers, let Tibotec know how much you’re counting on them at www.tibotecvirco.com.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    oceanblue65
    louisiana
    Louisiana


    TaintedloveDC
    Washington
    DC


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.